Vaccine with β-defensin 2-transduced leukemic cells activates innate and adaptive immunity to elicit potent antileukemia responses

Cancer Research

Volumn 66, Issue 2, 2006, Pages 1169-1176

  Ma, Xiao Tong ^a   Xu, Bin ^a   An, Li Li ^a   Dong, Cheng Ya ^a   Lin, Yong Min ^a   Shi, Yang ^a   Wu, Ke Fu ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN 2; CANCER VACCINE; MURINE BETA DEFENSIN 2; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER MODEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FEMALE; INNATE IMMUNITY; LEUKEMIA CELL; LEUKEMIA CELL LINE; MEMORY T LYMPHOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN SECRETION; VACCINATION;

ACUTE DISEASE; ANIMALS; ANTIBODY FORMATION; BETA-DEFENSINS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; IMMUNITY, NATURAL; IMMUNOLOGIC MEMORY; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOCYTIC; MICE; TRANSDUCTION, GENETIC;

EID: 31544445750     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2891     Document Type: Article

References (42)

1. Matzinger P. An innate sense of danger. Semin Immunol 1998;10:399-415.
2. Medzhitov R, Janeway C, Jr. Innate immunity. N Engl J Med 2000;343:338-44.
3. Medzhitov R, Janeway CA, Jr. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 1997;9:4-9.
4. Sweet MJ, Hume DA. Endotoxin signal transduction in macrophages. J Leukoc Biol 1996;60:8-26.
5. Tsutsumi-Ishii Y, Nagaoka I. NF-κB-mediated transcriptional regulation of human β-defensin-2 gene following lipopolysaccharide stimulation. J Leukoc Biol 2002;71:154-62.
6. Toshchakov V, Jones BW, Perera PY, et al. TLR4, but not TLR2, mediates IFN-β-induced STAT1α/β-dependent gene expression in macrophages. Nat Immunol 2002;3: 392-8.
7. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996;272:50-3.
8. Medzhitov R, Janeway CA, Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997; 91:295-8.
9. Yang D, Biragyn A, Kwak LW, Oppenheim JJ. Mammalian defensins in immunity: more than just microbicidal. Trends Immunol 2002;23:291-6.
10. Reis e Sousa C. Toll-like receptors and dendritic cells: for whom the bug tolls. Semin Immunol 2004;16: 27-34.
11. Biragyn A, Ruffini PA, Leifer CA, et al. Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2. Science 2002;298:1025-9.
12. Biragyn A, Belyakov IM, Chow YH, Dimitrov DS, Berzofsky JA, Kwak LW. DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood 2002;100: 1153-9.
13. Biragyn A, Surenhu M, Yang D, et al. Mediators of innate immunity that target immature, but not mature dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 2001;167:6644-53.
14. Dunussi-Joannopoulos K, Runyon K, Erickson J, Schaub RG, Hawley RG, Leonard JP. Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity. Blood 1999;94:4263-73.
15. Zhang B, Wu K-F, Lin Y-M, et al. Gene transfer of pro-IL-18 and IL-1β converting enzyme cDNA induces potent antitumor effects in L1210 cells. Leukemia 2004; 18:817-25.
16. Stripecke R, Skelton DC, Pattengale PK, Shimada H, Kohn DB. Combination of CD80 and granulocyte-macrophage colony-stimulating factor coexpression by a leukemia cell vaccine: preclinical studies in a murine model recapitulating Philadelphia chromosome-positive acute lymphoblastic leukemia. Hum Gene Ther 1999;10: 2109-22.
17. Dunussi-Joannopoulos K, Weinstein HJ, Nickerson PW, et al. Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in marine AML. Blood 1996;87: 2938-46.
18. Zibert A, Balzer S, Souquet M, et al. CCL3/MIP-1α is a potent immunostimulator when coexpressed with interleukin-2 or granulocyte-macrophage colony-stimulating factor in a leukemia/lymphoma vaccine. Hum Gene Ther 2004;15:21-34.
19. Dunussi-Joannopoulos K, Weinstein HJ, Arceci RJ, Croop JM. Gene therapy with B7.1 and GM-CSF vaccine in a murine AML model. J Pediatr Hematol Oncol 1997; 19:536-40.
20. Matulonis U, Dosiou C, Freeman G, et al. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. J Immunol 1996;156:1126-31.
21. Saudemont A, Buffenoir G, Denys A, et al. Gene transfer of CD154 and IL12 cDNA induces an antileukemic immunity in a murine model of acute leukemia Leukemia 2002;16:1637-44.
22. Stripecke R, Levine AM, Pullarkat V, Cardoso AA. Immunotherapy with acute leukemia cells modified into antigen-presenting cells: ex vivo culture and gene transfer methods. Leukemia 2002;16:1974-83.
23. Nair S, McLaughlin C, Weizer A, et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 2003;171:6275-82.
24. Sallusto F, Palermo B, Lenig D, et al. Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur J Immunol 1999;29:1617-25.
25. Sallusto F, Schaerli P, Loetscher P, et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 1998;28: 2760-9.
26. Kimura F, Douzono M, Ohta J, et al. Augmentation of antitumor immunity using genetically M-CSF-expressing L1210 cells. Exp Hematol 1996;24:360-3.
27. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001;13:114-9.
28. Raj PA, Dentino AR. Current status of defensins and their role in innate and adaptive immunity. FEMS Microbiol Lett 2002;206:9-18.
29. + T cell adoptive immunotherapy. Immunity 2000;13:265-76.
30. Costello RT, Rey J, Fauriat C, Gastaut JA, Olive D. New approaches in the immunotherapy of haematological malignancies. Eur J Haematol 2003;70:333-45.
31. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002;2:850-61.
32. Rajagopalan S, Long EO. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med 1999;189:1093-100.
33. Ponte M, Cantoni C, Biassoni R, et al. Inhibitory receptors sensing HLA-Gl molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor. Proc Natl Acad Sci U S A 1999;96:5674-9.
34. Lanier LL. Natural killer cells fertile with receptors for HLA-G? Proc Natl Acad Sci U S A 1999;96:5343-5.
35. Manski A, Bug G, Becker S, et al. Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. Exp Hematol 2005;33: 344-52.
36. Pende D, Spaggiari GM, Marcenaro S, et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 2005;105:2066-73.
37. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural killer cells and dendritic cells: "l'union fait la force." Blood 2005;106:2252-8.
38. Van Den Broeke LT, Daschbach E, Thomas EK, Andringa G, Berzofsky JA. Dendritic cell-mediated activation of adaptive and innate antitumor immunity. J Immunol 2003;171:5842-52.
39. Ewend MG, Thompson RC, Anderson R, et al. Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system. J Immunother 2000;23:438-48.
40. Lo CH, Lee SC, Wu PY, et al. Antitumor and antimetastatic activity of IL-23. J Immunol 2003;171:600-7.
41. Nagai H, Kara I, Horikawa T, Oka M, Kamidono S, Ichihashi M. Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration. J Invest Dermatol 2000;115:1059-64.
42. + T cell-independent pathway for antitumor CTL induction. Blood 2005;106:338-44.